EFFICACY AND TOLERANCE OF ORAL DIPYRONE VERSUS ORAL MORPHINE FOR CANCER PAIN

被引:49
|
作者
RODRIGUEZ, M
BARUTELL, C
RULL, M
GALVEZ, R
PALLARES, J
VIDAL, F
ALIAGA, L
MORENO, J
PUERTA, J
ORTIZ, P
机构
[1] EUROPHARMA SA, E-28020 MADRID, SPAIN
[2] HOSP CARLOS HAYA, MALAGA, SPAIN
[3] HOSP GEN VALLE HEBRON, BARCELONA, SPAIN
[4] HOSP SAN JUAN, REUS, SPAIN
[5] HOSP VIRGEN NIEVES, GRANADA, SPAIN
[6] HOSP LA FE, E-46009 VALENCIA, SPAIN
[7] HOSP GERMANS TRIAS & PUJOL, BADALONA, SPAIN
[8] HOSP SANTA CRUZ & SAN PABLO, BARCELONA, SPAIN
关键词
DIPYRONE; MORPHINE; ANALGESIA; EFFICACY; TOLERANCE; CANCER PAIN;
D O I
10.1016/0959-8049(94)90524-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a double-blind, randomised and parallel clinical trial, two oral doses of dipyrone (1 and 2 g) administered every 8 h were compared with 10 mg of oral morphine given every 4 h for the relief of chronic cancer pain. A total of 121 patients with cancer pain without gastric involvement participated in a 7-day treatment course and were allocated to receive either dipyrone 1 g (n = 41), dipyrone 2 g (n = 38) or morphine (n = 42). Drug efficacy was analysed according to the degree of pain relief using a 100-mm visual analogue scale, and the number of patients who decided to increase the dose of the analgesic drug on day 4. The analgesic effect of dipyrone, 2 g every 8 h, was similar to that of morphine. The efficacy of both schedules was significantly greater than that of dipyrone, 1 g every 8 h. Dipyrone at either 1 or 2 g doses tended to be better tolerated than morphine, although the differences were not statistically significant.
引用
收藏
页码:584 / 587
页数:4
相关论文
共 50 条
  • [31] Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management
    Lauretti, GR
    Lima, ICPR
    Reis, MP
    Prado, WA
    Pereira, NL
    ANESTHESIOLOGY, 1999, 90 (06) : 1528 - 1533
  • [32] ORAL MORPHINE MIXTURE FOR INTRACTABLE PAIN
    AJEMIAN, I
    CANADIAN FAMILY PHYSICIAN, 1977, 23 (DEC) : 52 - 53
  • [33] A multicentre evaluation of the analgesic efficacy and toxicity of oral Ketorolac versus Diclofenac in cancer pain
    Pannuti, F
    DellaCuna, GR
    Ventaffrida, V
    Preti, P
    Cricca, A
    Strocchi, E
    Camaggi, CM
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1228 - 1228
  • [34] A COMPARATIVE-STUDY OF THE EFFICACY AND PHARMACOKINETICS OF ORAL METHADONE AND MORPHINE IN THE TREATMENT OF SEVERE PAIN IN PATIENTS WITH CANCER
    GOURLAY, GK
    CHERRY, DA
    COUSINS, MJ
    PAIN, 1986, 25 (03) : 297 - 312
  • [35] EFFICACY AND TOLERANCE OF ORAL NALBUPHIN
    KAGANAS, G
    BARONEKAGANAS, I
    MEDIZINISCHE WELT, 1988, 39 (49-50): : 1554 - 1556
  • [36] PHARMACOLOGICAL TREATMENT OF CANCER PAIN WITH SPECIAL REFERENCE TO THE ORAL USE OF MORPHINE
    RANE, A
    SAWE, J
    DAHLSTROM, B
    PAALZOW, L
    KAGER, L
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1982, 26 : 97 - 103
  • [37] EXPERIENCE WITH A CONTROLLED-RELEASE ORAL MORPHINE FOR CANCER PAIN MANAGEMENT
    KIM, BS
    CHUNG, HC
    POSTGRADUATE MEDICAL JOURNAL, 1991, 67 : S82 - S86
  • [38] The relative milligram potency ratio of intravenous to oral morphine in cancer pain
    Mahmoud, F
    Walsh, TD
    Sarhill, N
    Nelson, K
    Davis, M
    LeGrand, S
    Rivera, N
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 477 - 477
  • [39] The relative milligram potency ratio of intravenous to oral morphine in cancer pain
    Mahmoud, F
    Walsh, D
    Sarhill, N
    Legrand, S
    Davis, M
    Lagman, R
    Rivera, N
    JOURNAL OF PALLIATIVE CARE, 2002, 18 (03) : 236 - 236
  • [40] TRANSDERMAL FENTANYL ALTERNATIVE TO ORAL SR MORPHINE IN THE TREATMENT OF CANCER PAIN
    Mascia, L.
    Aloi, M. B.
    Bruder, F.
    Defraia, E.
    Farci, D.
    Ferreli, L.
    Gutmann, G.
    Mascia, V.
    ANNALS OF ONCOLOGY, 2004, 15 : 115 - 115